Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Epigenomics Reports 81 Percent Drop in Q2 Revenues; Takeover Bid Fails

Epigenomics Reports 81 Percent Drop in Q2 Revenues; Takeover Bid Fails

Aug 09, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Epigenomics reported today that its second quarter revenues dropped 81 percent due to lower orders of its Epi proColon colorectal cancer test and a continued lack of reimbursement coverage for its products.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

    Premium

  2. FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

  3. CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

  4. Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

  5. Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.